These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31807797)

  • 41. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
    Taverner S; Eng C; Watson R; George S; Edwards A; Williams DM; Stephens JW
    Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes.
    Raven LM; Muir CA; Greenfield JR
    Med J Aust; 2023 Oct; 219(7):293-294. PubMed ID: 37549922
    [No Abstract]   [Full Text] [Related]  

  • 43. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-An expert consensus statement.
    Liew A; Lydia A; Matawaran BJ; Susantitaphong P; Tran HTB; Lim LL
    Nephrology (Carlton); 2023 Aug; 28(8):415-424. PubMed ID: 37153973
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition.
    Sanusi I; Sarnowski A; Russell-Jones D; Forni LG
    J Crit Care; 2020 Jun; 57():19-22. PubMed ID: 32007835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
    Miyauchi M; Toyoda M; Fukagawa M
    Intern Med; 2017; 56(13):1673-1678. PubMed ID: 28674356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Shi N; Shi Y; Xu J; Si Y; Yang T; Zhang M; Ng DM; Li X; Xie F
    Front Public Health; 2021; 9():668368. PubMed ID: 34164370
    [No Abstract]   [Full Text] [Related]  

  • 47. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
    Perry RJ; Rabin-Court A; Song JD; Cardone RL; Wang Y; Kibbey RG; Shulman GI
    Nat Commun; 2019 Feb; 10(1):548. PubMed ID: 30710078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ketonuria in an adult with Prader-Willi syndrome and diabetes mellitus: A case report.
    Xu X; Wang D; Pan H; Li J; Li B; He Z
    Medicine (Baltimore); 2024 Jan; 103(4):e37096. PubMed ID: 38277514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery.
    Singh S; Rushakoff RJ; Neinstein AB
    J Diabetes Sci Technol; 2019 May; 13(3):605-606. PubMed ID: 30931610
    [No Abstract]   [Full Text] [Related]  

  • 50. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
    Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
    Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
    Danne T; Garg S; Peters AL; Buse JB; Mathieu C; Pettus JH; Alexander CM; Battelino T; Ampudia-Blasco FJ; Bode BW; Cariou B; Close KL; Dandona P; Dutta S; Ferrannini E; Fourlanos S; Grunberger G; Heller SR; Henry RR; Kurian MJ; Kushner JA; Oron T; Parkin CG; Pieber TR; Rodbard HW; Schatz D; Skyler JS; Tamborlane WV; Yokote K; Phillip M
    Diabetes Care; 2019 Jun; 42(6):1147-1154. PubMed ID: 30728224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
    Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
    Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Mannucci E; Monami M
    Diabetes Obes Metab; 2019 Aug; 21(8):1871-1877. PubMed ID: 30972917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors.
    Chow E; Clement S; Garg R
    BMJ Open Diabetes Res Care; 2023 Oct; 11(5):. PubMed ID: 37797963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
    Blau JE; Tella SH; Taylor SI; Rother KI
    Diabetes Metab Res Rev; 2017 Nov; 33(8):. PubMed ID: 28736981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.
    Alkabbani W; Pelletier R; Beazely MA; Labib Y; Quan B; Gamble JM
    Drug Saf; 2022 Mar; 45(3):287-295. PubMed ID: 35247195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Euglycemic Diabetic Ketoacidosis Caused by Alcoholic Pancreatitis and Starvation Ketosis.
    Han HJ; Cole AE; Verma A
    J Gen Intern Med; 2023 Apr; 38(5):1299-1301. PubMed ID: 36689144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.